NEW YORK (GenomeWeb) – Kailos Genetics has signed an agreement to allow Illumina to market its TargetRich research solutions for pharmacogenetic target enrichment.
The products included in the marketing and promotions arrangement are TargetRich PGxComplete and Kailos Blue. According to Kailos, PGxComplete is a research use only reagent for targeting genes that are associated with response to more than 100 medications. Kailos Blue is the company's automated data analysis solution and reporting software used with TargetRich reagents.
Kailos is an Illumina BaseSpace Suite ecosystem partner, which allows the TargetRich solution to pull data from the BaseSpace Sequence Hub and stream data in real time from the sequencing instrument.
By combining TargetRich chemistry and Kailos Blue analysis tools with Illumina's next-generation sequencing systems and reagents, the partners are hoping to streamline workflows for customers. "The joint solution makes it possible for research laboratories currently standardized on other technologies to convert to NGS," Kailos CEO Brian Pollock said in a statement. "Working with Illumina, we expect to expand the use of NGS solutions to a wider set of laboratories."